These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 33140101)

  • 1. Immunotherapy for advanced melanoma: current situation in Japan.
    Kato J; Uhara H
    Jpn J Clin Oncol; 2021 Jan; 51(1):3-9. PubMed ID: 33140101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.
    Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma.
    Tang B; Mo J; Yan X; Duan R; Chi Z; Cui C; Si L; Kong Y; Mao L; Li S; Zhou L; Lian B; Wang X; Bai X; Xu H; Li C; Dai J; Guo J; Sheng X
    Eur J Cancer; 2021 Oct; 156():83-92. PubMed ID: 34425407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
    Komatsubara KM; Carvajal RD
    Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors in melanoma.
    Carlino MS; Larkin J; Long GV
    Lancet; 2021 Sep; 398(10304):1002-1014. PubMed ID: 34509219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
    Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.
    Bloem M; van Not OJ; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Blokx WAM; Boers-Sonderen MJ; Bonenkamp JJ; de Groot JB; Haanen JB; Hospers GAP; Kapiteijn EW; de Meza MM; Piersma D; van Rijn RS; Stevense-den Boer MAM; van der Veldt AAM; Vreugdenhil G; van den Eertwegh AJM; Suijkerbuijk KPM; Wouters MWJM
    Int J Cancer; 2024 Oct; 155(8):1455-1465. PubMed ID: 38922879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.
    Babacan NA; Eroglu Z
    Curr Oncol Rep; 2020 Mar; 22(4):38. PubMed ID: 32198651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study.
    Chatziioannou E; Higuita LMS; Kreft S; Kandolf L; Dujovic B; Reinhardt L; Tamara E; Marquez-Rodas I; Fortuna ARFP; Nübling A; Niessner H; Forschner A; Garbe C; Popovic A; Mirjana B; Meier F; Eigentler T; Leiter U; Flatz L; Sinnberg T; Amaral T
    ESMO Open; 2024 Aug; 9(8):103661. PubMed ID: 39096893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving cancer resistance to anti-PD-1/PD-L1 antibodies in melanoma: Comprehensive insights with future prospects.
    Li W; Gu J; Fan H; Zhang L; Guo J; Si L
    Crit Rev Oncol Hematol; 2024 Sep; 201():104426. PubMed ID: 38908767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
    Levine LS; Mahuron KM; Tsai KK; Wu C; Mattis DM; Pauli ML; Oglesby A; Lee JC; Spitzer MH; Krummel MF; Algazi AP; Rosenblum MD; Alvarado M; Daud AI
    Ann Surg Oncol; 2020 Oct; 27(11):4122-4130. PubMed ID: 32488521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice.
    van Zeijl MCT; van den Eertwegh AJM; Wouters MWJM; de Wreede LC; Aarts MJB; van den Berkmortel FWPJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven JJM; Haanen JBAG
    Int J Cancer; 2022 Jan; 150(2):317-326. PubMed ID: 34520567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients.
    Zaremba A; Eggermont AMM; Robert C; Dummer R; Ugurel S; Livingstone E; Ascierto PA; Long GV; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 Sep; 155():268-280. PubMed ID: 34392069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of immune checkpoint inhibitors in different types of melanoma.
    Rossi E; Schinzari G; Maiorano BA; Indellicati G; Di Stefani A; Pagliara MM; Fragomeni SM; De Luca EV; Sammarco MG; Garganese G; Galli J; Blasi MA; Paludetti G; Scambia G; Peris K; Tortora G
    Hum Vaccin Immunother; 2021 Jan; 17(1):4-13. PubMed ID: 32663057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
    Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Therapies for Melanoma.
    Buchbinder EI
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):99-109. PubMed ID: 33759776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local and disease control for nasal melanoma treated with radiation and concomitant anti-programmed death 1 antibody.
    Hanaoka Y; Tanemura A; Takafuji M; Kiyohara E; Arase N; Suzuki O; Isohashi F; Ogawa K; Fujimoto M
    J Dermatol; 2020 Apr; 47(4):423-425. PubMed ID: 32030784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.